Amerikanische Gesellschaft für Hirudotherapie

Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis

Case report published in Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2011)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportKlinische StudienSicherheit & InfektionskontrolleOng A et al. · Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011

Abstract

Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine with pleiotropic effects. Currently, TNF-α inhibitors are approved by the Food and Drug Administration for a number of diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, and ulcerative colitis. We report a patient with seropositive rheumatoid arthritis with concurrent primary myelofibrosis, who had transfusion-dependent anemia and moderate thrombocytopenia that reversed during treatment with adalimumab. Rheumatoid arthritis and myeloproliferative disorder or myelodysplastic disorder often coexist, and treatment with standard immunosuppressants becomes complex. This report adds to the accumulating evidence of the safety of TNF-α inhibitors when primary myelofibrosis is present and generates discussion for further exploration of the potential therapeutic benefit of TNF-α inhibitors in cytopenias associated with primary myelofibrosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAdalimumabAnemiaAntibodies, Monoclonal, HumanizedArthritis, RheumatoidBlood TransfusionComorbidityHumansMaleMiddle AgedPrimary MyelofibrosisTreatment OutcomeTumor Necrosis Factor-alpha

Zusammenfassung

Tumor necrosis factor (TNF-) is a proinflammatory cytokine with pleiotropic effects.

Warum dies für die Hirudotherapie relevant ist

This case report describes a patient with concurrent seropositive rheumatoid arthritis and primary myelofibrosis whose transfusion-dependent anemia and moderate thrombocytopenia reversed during treatment with adalimumab, a tumor necrosis factor-alpha (TNF-α) inhibitor. The report adds to accumulating evidence regarding the safety of TNF-α inhibitors when primary myelofibrosis is present and generates discussion about their potential therapeutic benefit for cytopenias associated with the condition. The abstract provides no data on leeches, hirudotherapy, hirudin, or any components of the leech secretome, nor does it address anticoagulation or related therapeutic mechanisms. Therefore, this article has no apparent relevance to the American Society of Hirudotherapy based on its abstract.

Zitation

Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis

Ong A et al. · Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.